Chris De Savi

1.7k total citations
29 papers, 519 citations indexed

About

Chris De Savi is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Chris De Savi has authored 29 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Organic Chemistry and 9 papers in Oncology. Recurrent topics in Chris De Savi's work include Carbohydrate Chemistry and Synthesis (4 papers), Protease and Inhibitor Mechanisms (4 papers) and Advanced Breast Cancer Therapies (3 papers). Chris De Savi is often cited by papers focused on Carbohydrate Chemistry and Synthesis (4 papers), Protease and Inhibitor Mechanisms (4 papers) and Advanced Breast Cancer Therapies (3 papers). Chris De Savi collaborates with scholars based in United Kingdom, United States and Australia. Chris De Savi's co-authors include Matthew T. Tudge, Ian Paterson, Lisbet Kværnø, David L. Hughes, Keith G. Watson, Martin G. Banwell, G. T. Crisp, Yulin Jiang, David C. R. Hockless and Attilla Ting and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Chris De Savi

27 papers receiving 498 citations

Peers

Chris De Savi

ONCOL

PRM

PHARM

Matthew E. Voss United States

Maria Gabriella Brasca Italy

Peter D. Gorycki United States

Francis X. Tavares United States

Laura Maccari Italy

Shigeki Kashimoto Japan

Keiji Kamiyama Japan

R. Hendricks United States

Stefan Gradl United States

Gwan Sun Lee South Korea

Matthew E. Voss United States

Chris De Savi

274 ×1.0

281 ×1.3

134 ×1.0

ONCOL

133 ×1.8

PRM

26 ×0.5

PHARM

Citations per year, relative to Chris De Savi Chris De Savi (= 1×) peers Matthew E. Voss

Countries citing papers authored by Chris De Savi

Since Specialization

Citations

This map shows the geographic impact of Chris De Savi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris De Savi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris De Savi more than expected).

Fields of papers citing papers by Chris De Savi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris De Savi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris De Savi. The network helps show where Chris De Savi may publish in the future.

Co-authorship network of co-authors of Chris De Savi

This figure shows the co-authorship network connecting the top 25 collaborators of Chris De Savi. A scholar is included among the top collaborators of Chris De Savi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris De Savi. Chris De Savi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sullivan, Jeffrey, Crystal Brown, Michele Mayo, et al.. (2022). STAT3 degraders inhibit cellular activation, cytokine production, and Th17 development, resulting in inhibition of autoimmunity in the MOG-EAE model of CNS inflammation.. The Journal of Immunology. 208(Supplement_1). 60.07–60.07. 1 indexed citations

Dey, Joyoti, Phillip Liu, Michele Mayo, et al.. (2021). 603 Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy. SHILAP Revista de lepidopterología. A633–A633.

Schalm, Stefanie S., Sangbin Lim, Rich Woessner, et al.. (2020). 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Annals of Oncology. 31. S839–S839. 43 indexed citations

Schalm, Stefanie S., Sangbin Lim, Rich Woessner, et al.. (2020). 384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Annals of Oncology. 31. S1391–S1391. 12 indexed citations

Savi, Chris De, David L. Hughes, & Lisbet Kværnø. (2020). Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. Organic Process Research & Development. 24(6). 940–976. 76 indexed citations

Savi, Chris De, Robert H. Bradbury, Alfred A. Rabow, et al.. (2015). Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. Cancer Research. 75(15_Supplement). 3650–3650. 4 indexed citations

Savi, Chris De, Rhona J. Cox, Daniel J. Warner, et al.. (2014). Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD. Journal of Medicinal Chemistry. 57(11). 4661–4676. 28 indexed citations

Savi, Chris De, David Waterson, Andrew R. Pape, et al.. (2013). Hydantoin based inhibitors of MMP13—Discovery of AZD6605. Bioorganic & Medicinal Chemistry Letters. 23(16). 4705–4712. 18 indexed citations

Savi, Chris De, Andrew R. Pape, John G. Cumming, et al.. (2011). The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis. Bioorganic & Medicinal Chemistry Letters. 21(5). 1376–1381. 18 indexed citations

10.

Savi, Chris De, Andrew R. Pape, John G. Cumming, et al.. (2011). Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorganic & Medicinal Chemistry Letters. 21(11). 3301–3306. 13 indexed citations

11.

Savi, Chris De, Andrew Morley, Galith Karoutchi, et al.. (2011). Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. Bioorganic & Medicinal Chemistry Letters. 22(1). 271–277. 12 indexed citations

12.

Savi, Chris De, Andrew Morley, Attilla Ting, et al.. (2011). Selective non zinc binding inhibitors of MMP13. Bioorganic & Medicinal Chemistry Letters. 21(14). 4215–4219. 18 indexed citations

13.

Ward, John W., et al.. (2010). Construction of perhydro indol-2-ones by a methoxide catalyzed deacetylation–Michael–aldol cascade. Chemical Communications. 46(10). 1691–1691. 13 indexed citations

14.

Stevenson, Neil G., et al.. (2006). Furan Diels-Alder Cycloaddition Approach to the Highly Oxygenated Core of Scyphostatin. Synlett. 2006(14). 2272–2274. 2 indexed citations

15.

Paterson, Ian, Chris De Savi, & Matthew T. Tudge. (2001). Total Synthesis of the Microtubule-Stabilizing Agent (−)-Laulimalide. Organic Letters. 3(20). 3149–3152. 92 indexed citations

16.

Paterson, Ian, Chris De Savi, & Matthew T. Tudge. (2000). Synthesis of the Macrocyclic Core of Laulimalide. Organic Letters. 3(2). 213–216. 32 indexed citations

17.

Crisp, G. T., et al.. (1997). Elaboration of the side-chain of amino acid derivatives by palladium catalysed couplings. Tetrahedron. 53(51). 17489–17500. 24 indexed citations

18.

Corti, A, et al.. (1991). Early severe infections after orthotopic liver transplantation.. PubMed. 23(3). 1964–1964. 9 indexed citations

19.

Scarabelli, C, et al.. (1978). [Role of loco-regional chemotherapy in the treatment of tumors of the cervix].. PubMed. 29(7-8). 611–26. 2 indexed citations

20.

Savi, Chris De, et al.. (1958). [Pharmacological & therapeutic effects of a synthetic, orally active progestogen].. PubMed. 8(4). 210–6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact